Aethlon Medical (NASDAQ:AEMD) Issues Earnings Results, Beats Expectations By $2.86 EPS

Aethlon Medical (NASDAQ:AEMD) issued its earnings results on Wednesday. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.46) by $2.86, FiscalAI reports.

Aethlon Medical Price Performance

NASDAQ AEMD traded up $0.08 during midday trading on Wednesday, hitting $2.02. 773,564 shares of the company traded hands, compared to its average volume of 344,208. Aethlon Medical has a 52 week low of $1.36 and a 52 week high of $27.40. The company’s 50-day simple moving average is $2.23 and its 200-day simple moving average is $2.51. The company has a market cap of $3.17 million, a PE ratio of -0.14 and a beta of 1.49.

Institutional Investors Weigh In On Aethlon Medical

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC bought a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical as of its most recent SEC filing. 1.99% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a report on Monday, April 20th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Aethlon Medical currently has an average rating of “Reduce”.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.